Concepts (123)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 1 | 4 | 2022 | 565 | 1.870 |
Why?
|
| Blood Glucose Self-Monitoring | 3 | 2022 | 54 | 1.400 |
Why?
|
| Diabetes Mellitus, Type 2 | 7 | 2024 | 1180 | 1.180 |
Why?
|
| Diabetes Mellitus | 6 | 2025 | 743 | 1.140 |
Why?
|
| Blood Glucose | 5 | 2022 | 837 | 0.990 |
Why?
|
| Propensity Score | 1 | 2024 | 149 | 0.880 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2023 | 264 | 0.710 |
Why?
|
| Appointments and Schedules | 2 | 2023 | 54 | 0.690 |
Why?
|
| Telemedicine | 2 | 2020 | 189 | 0.670 |
Why?
|
| Nebulizers and Vaporizers | 1 | 2020 | 57 | 0.660 |
Why?
|
| Insulin Infusion Systems | 1 | 2018 | 37 | 0.620 |
Why?
|
| Cost-Benefit Analysis | 5 | 2022 | 465 | 0.600 |
Why?
|
| Hypothyroidism | 3 | 2024 | 242 | 0.580 |
Why?
|
| Inpatients | 1 | 2020 | 311 | 0.550 |
Why?
|
| Patient Education as Topic | 1 | 2020 | 364 | 0.540 |
Why?
|
| Insulin | 2 | 2018 | 1148 | 0.540 |
Why?
|
| Hypertension | 1 | 2022 | 747 | 0.540 |
Why?
|
| Medicaid | 3 | 2024 | 238 | 0.510 |
Why?
|
| Adult | 16 | 2025 | 26704 | 0.450 |
Why?
|
| Thyroxine | 3 | 2024 | 354 | 0.450 |
Why?
|
| Quality of Life | 4 | 2023 | 1673 | 0.420 |
Why?
|
| Population Health | 2 | 2023 | 33 | 0.410 |
Why?
|
| Primary Health Care | 5 | 2024 | 352 | 0.390 |
Why?
|
| Asthma | 1 | 2020 | 983 | 0.390 |
Why?
|
| Job Satisfaction | 2 | 2025 | 79 | 0.380 |
Why?
|
| Humans | 32 | 2025 | 89613 | 0.360 |
Why?
|
| United States | 8 | 2024 | 7050 | 0.360 |
Why?
|
| Quality-Adjusted Life Years | 3 | 2022 | 144 | 0.360 |
Why?
|
| Community Health Centers | 4 | 2025 | 117 | 0.350 |
Why?
|
| Ambulatory Care Facilities | 2 | 2022 | 111 | 0.340 |
Why?
|
| Delivery of Health Care | 2 | 2024 | 435 | 0.320 |
Why?
|
| Thyrotropin | 3 | 2024 | 289 | 0.320 |
Why?
|
| Cross-Sectional Studies | 6 | 2024 | 1725 | 0.310 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2023 | 260 | 0.310 |
Why?
|
| Depression | 5 | 2023 | 512 | 0.300 |
Why?
|
| Hormone Replacement Therapy | 2 | 2024 | 85 | 0.250 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 2 | 2022 | 36 | 0.240 |
Why?
|
| Male | 11 | 2025 | 42488 | 0.240 |
Why?
|
| Middle Aged | 8 | 2025 | 26012 | 0.240 |
Why?
|
| Triiodothyronine | 2 | 2023 | 345 | 0.240 |
Why?
|
| Aged | 9 | 2024 | 19158 | 0.230 |
Why?
|
| Insurance Claim Review | 1 | 2024 | 45 | 0.230 |
Why?
|
| Texas | 1 | 2024 | 116 | 0.230 |
Why?
|
| Female | 11 | 2025 | 46401 | 0.230 |
Why?
|
| Thyroid Hormones | 2 | 2023 | 330 | 0.220 |
Why?
|
| Physicians | 2 | 2023 | 691 | 0.220 |
Why?
|
| Burnout, Professional | 1 | 2025 | 102 | 0.210 |
Why?
|
| Patient Portals | 1 | 2023 | 18 | 0.210 |
Why?
|
| Patient Care Bundles | 1 | 2023 | 21 | 0.210 |
Why?
|
| Hypoglycemic Agents | 3 | 2022 | 351 | 0.210 |
Why?
|
| Hyperthyroidism | 1 | 2022 | 75 | 0.200 |
Why?
|
| Office Visits | 1 | 2022 | 50 | 0.190 |
Why?
|
| Health Care Costs | 1 | 2023 | 236 | 0.190 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2022 | 102 | 0.190 |
Why?
|
| Patient Outcome Assessment | 1 | 2022 | 84 | 0.190 |
Why?
|
| Social Determinants of Health | 1 | 2022 | 103 | 0.190 |
Why?
|
| Metformin | 1 | 2022 | 124 | 0.180 |
Why?
|
| Psychiatry | 1 | 2022 | 82 | 0.180 |
Why?
|
| Financing, Organized | 1 | 2020 | 12 | 0.180 |
Why?
|
| Substance Abuse Treatment Centers | 1 | 2020 | 24 | 0.180 |
Why?
|
| Prospective Studies | 3 | 2024 | 4309 | 0.170 |
Why?
|
| Chronic Pain | 1 | 2022 | 163 | 0.170 |
Why?
|
| Computer Simulation | 1 | 2024 | 1101 | 0.170 |
Why?
|
| Health Services Accessibility | 2 | 2021 | 433 | 0.170 |
Why?
|
| Colorado | 1 | 2019 | 37 | 0.170 |
Why?
|
| Adolescent | 3 | 2022 | 9305 | 0.170 |
Why?
|
| Comparative Effectiveness Research | 1 | 2020 | 53 | 0.170 |
Why?
|
| Intention to Treat Analysis | 1 | 2019 | 72 | 0.160 |
Why?
|
| Opioid-Related Disorders | 1 | 2022 | 193 | 0.160 |
Why?
|
| Physicians, Primary Care | 1 | 2020 | 105 | 0.160 |
Why?
|
| Allied Health Personnel | 1 | 2018 | 20 | 0.150 |
Why?
|
| Monitoring, Ambulatory | 1 | 2018 | 32 | 0.150 |
Why?
|
| Feasibility Studies | 1 | 2020 | 782 | 0.140 |
Why?
|
| Hypoglycemia | 1 | 2018 | 107 | 0.140 |
Why?
|
| Hospitals | 3 | 2023 | 303 | 0.130 |
Why?
|
| Reproducibility of Results | 1 | 2022 | 2763 | 0.130 |
Why?
|
| Substance-Related Disorders | 1 | 2020 | 418 | 0.130 |
Why?
|
| Patient Satisfaction | 1 | 2018 | 460 | 0.120 |
Why?
|
| Electronic Health Records | 1 | 2018 | 351 | 0.120 |
Why?
|
| Hospitalization | 3 | 2024 | 880 | 0.110 |
Why?
|
| Nutrition Surveys | 2 | 2023 | 111 | 0.100 |
Why?
|
| Sodium | 2 | 2022 | 331 | 0.090 |
Why?
|
| Young Adult | 2 | 2019 | 6368 | 0.090 |
Why?
|
| Glucose | 2 | 2022 | 629 | 0.080 |
Why?
|
| Pilot Projects | 2 | 2022 | 870 | 0.070 |
Why?
|
| Morale | 1 | 2025 | 16 | 0.060 |
Why?
|
| Attitude of Health Personnel | 2 | 2022 | 652 | 0.060 |
Why?
|
| Brazil | 1 | 2024 | 75 | 0.060 |
Why?
|
| Self-Management | 1 | 2024 | 42 | 0.060 |
Why?
|
| Diagnosis-Related Groups | 1 | 2023 | 21 | 0.060 |
Why?
|
| Interviews as Topic | 1 | 2025 | 344 | 0.060 |
Why?
|
| Maryland | 1 | 2023 | 43 | 0.050 |
Why?
|
| Demography | 1 | 2023 | 183 | 0.050 |
Why?
|
| Thyroid Function Tests | 1 | 2023 | 120 | 0.050 |
Why?
|
| Housing | 1 | 2023 | 46 | 0.050 |
Why?
|
| Sodium-Glucose Transporter 2 | 1 | 2022 | 4 | 0.050 |
Why?
|
| Health Personnel | 1 | 2025 | 214 | 0.050 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2022 | 47 | 0.050 |
Why?
|
| Telephone | 1 | 2022 | 35 | 0.050 |
Why?
|
| Rural Population | 1 | 2023 | 146 | 0.050 |
Why?
|
| Data Collection | 1 | 2023 | 376 | 0.050 |
Why?
|
| Poverty | 1 | 2023 | 183 | 0.050 |
Why?
|
| Social Support | 1 | 2023 | 216 | 0.050 |
Why?
|
| Longitudinal Studies | 1 | 2024 | 1076 | 0.050 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2022 | 193 | 0.040 |
Why?
|
| Opiate Substitution Treatment | 1 | 2020 | 41 | 0.040 |
Why?
|
| Medicare | 1 | 2023 | 426 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2023 | 952 | 0.040 |
Why?
|
| Emergency Service, Hospital | 1 | 2024 | 524 | 0.040 |
Why?
|
| Quality Improvement | 1 | 2023 | 455 | 0.040 |
Why?
|
| Length of Stay | 1 | 2022 | 743 | 0.040 |
Why?
|
| Emotions | 1 | 2022 | 352 | 0.040 |
Why?
|
| Patient Selection | 1 | 2022 | 677 | 0.040 |
Why?
|
| Cardiovascular Diseases | 1 | 2024 | 714 | 0.040 |
Why?
|
| Biomarkers | 1 | 2024 | 1768 | 0.040 |
Why?
|
| Analgesics, Opioid | 1 | 2022 | 451 | 0.040 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2022 | 606 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2023 | 2878 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2021 | 2304 | 0.030 |
Why?
|
| Child | 1 | 2024 | 7216 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2020 | 2646 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2022 | 8218 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2022 | 9127 | 0.020 |
Why?
|